^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    genistein nanosuspension (BIO 300)

    i
    Other names: BIO 300, BIO-300, BIO300
    Associations

    News

    Trials
    Company:
    Humanetics
    Drug class:
    Selective estrogen receptor β agonist
    Related drugs:
    Associations

    News

    Trials
    4ms
    Phase 1 BIO 300 Oral Suspension (clinicaltrials.gov)
    P1, N=56, Completed, Humanetics Corporation | Recruiting --> Completed
    Trial completion
    |
    genistein nanosuspension (BIO 300)
    1year
    Phase 1 BIO 300 Oral Suspension (clinicaltrials.gov)
    P1, N=56, Recruiting, Humanetics Corporation | Not yet recruiting --> Recruiting
    Enrollment open
    |
    genistein nanosuspension (BIO 300)
    1year
    Phase 1 BIO 300 Oral Suspension (clinicaltrials.gov)
    P1, N=56, Not yet recruiting, Humanetics Corporation
    New P1 trial
    |
    genistein nanosuspension (BIO 300)
    over1year
    BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Humanetics Corporation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1) • IL1B (Interleukin 1, beta)
    |
    genistein nanosuspension (BIO 300)
    almost2years
    BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients (clinicaltrials.gov)
    P2, N=50, Recruiting, Humanetics Corporation | Trial completion date: Mar 2024 --> Apr 2025 | Trial primary completion date: Jun 2023 --> Jun 2024
    Trial completion date • Trial primary completion date
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1) • IL1B (Interleukin 1, beta)
    |
    genistein nanosuspension (BIO 300)
    over2years
    Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients with Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy. (PubMed, Int J Radiat Oncol Biol Phys)
    The low toxicity rates, along with the pharmacodynamic results and tumor response rates, support further investigation of BIO 300 as an effective radioprotector.
    P1/2 data • Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    carboplatin • paclitaxel • genistein nanosuspension (BIO 300)
    over2years
    The radioprotectant nano-genistein enhances radiotherapy efficacy of lung tumors in mice. (PubMed, Transl Lung Cancer Res)
    There were no treatment-related histopathological findings noted in the skin adjacent to the tumor, esophagus, or uterus. These results, including the safety following extended dosing, support the continued evaluation of nano-genistein as an adjunctive treatment for patients with NSCLC undergoing radiotherapy and serve as the basis of a phase 1b/2a multicenter clinical trial.
    Preclinical • Journal
    |
    genistein nanosuspension (BIO 300)